Pyxis Oncology (PYXS)

• Market cap: $83.7M
• 1 day: -2.88%
• 5 days: 10.66%
• 1 month: 9.76%
• 3 months: 8.87%
• 6 months: 19.47%
• Year to date: -20.12%
• 1 year: -64.57%
• 5 years: -89.77%
• 10 years: -89.77%
• Sector: Healthcare
• Industry: Biotechnology

About: Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

Employees: 44

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

700% more call options, than puts

Call options by funds: $16K | Put options by funds: $2K

1% more capital invested

Capital invested by funds: $29.6M [Q1] → $30.1M (+$431K) [Q2]

4.99% less ownership

Funds ownership: 49.11% [Q1] → 44.13% (-4.99%) [Q2]

18% less funds holding

Funds holding: 88 [Q1] → 72 (-16) [Q2]

22% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 23

48% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 29

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $5 270% upside
• Avg. target: $5 270% upside
• High target: $5 270% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Swayampakula Ramakanth

270% upside $5

Buy Reiterated

19 Aug 2025